JP2002543116A5 - - Google Patents

Download PDF

Info

Publication number
JP2002543116A5
JP2002543116A5 JP2000614984A JP2000614984A JP2002543116A5 JP 2002543116 A5 JP2002543116 A5 JP 2002543116A5 JP 2000614984 A JP2000614984 A JP 2000614984A JP 2000614984 A JP2000614984 A JP 2000614984A JP 2002543116 A5 JP2002543116 A5 JP 2002543116A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000614984A
Other languages
Japanese (ja)
Other versions
JP2002543116A (ja
JP4975214B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/011129 external-priority patent/WO2000066099A2/en
Publication of JP2002543116A publication Critical patent/JP2002543116A/ja
Publication of JP2002543116A5 publication Critical patent/JP2002543116A5/ja
Application granted granted Critical
Publication of JP4975214B2 publication Critical patent/JP4975214B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000614984A 1999-04-30 2000-04-26 単位製剤 Expired - Lifetime JP4975214B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13203699P 1999-04-30 1999-04-30
US60/132,036 1999-04-30
PCT/US2000/011129 WO2000066099A2 (en) 1999-04-30 2000-04-26 Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction

Publications (3)

Publication Number Publication Date
JP2002543116A JP2002543116A (ja) 2002-12-17
JP2002543116A5 true JP2002543116A5 (cg-RX-API-DMAC7.html) 2005-12-22
JP4975214B2 JP4975214B2 (ja) 2012-07-11

Family

ID=22452153

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000614984A Expired - Lifetime JP4975214B2 (ja) 1999-04-30 2000-04-26 単位製剤
JP2000126472A Pending JP2000336043A (ja) 1999-04-30 2000-04-26 医薬製造品

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2000126472A Pending JP2000336043A (ja) 1999-04-30 2000-04-26 医薬製造品

Country Status (47)

Country Link
EP (2) EP1173181B3 (cg-RX-API-DMAC7.html)
JP (2) JP4975214B2 (cg-RX-API-DMAC7.html)
KR (2) KR100577057B1 (cg-RX-API-DMAC7.html)
CN (2) CN1196487C (cg-RX-API-DMAC7.html)
AT (1) ATE251908T1 (cg-RX-API-DMAC7.html)
AU (3) AU769946C (cg-RX-API-DMAC7.html)
BE (1) BE1012957A5 (cg-RX-API-DMAC7.html)
BR (2) BR0010181A (cg-RX-API-DMAC7.html)
CA (2) CA2371684C (cg-RX-API-DMAC7.html)
CH (2) CH1173181H1 (cg-RX-API-DMAC7.html)
CO (1) CO5170493A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ296534B6 (cg-RX-API-DMAC7.html)
DE (3) DE10021266A1 (cg-RX-API-DMAC7.html)
DK (2) DK200000677A (cg-RX-API-DMAC7.html)
DZ (1) DZ3171A1 (cg-RX-API-DMAC7.html)
EA (2) EA005416B1 (cg-RX-API-DMAC7.html)
ES (2) ES2187234A1 (cg-RX-API-DMAC7.html)
FI (1) FI20000976A7 (cg-RX-API-DMAC7.html)
FR (1) FR2795646B1 (cg-RX-API-DMAC7.html)
GB (1) GB2351663A (cg-RX-API-DMAC7.html)
GR (1) GR1003575B (cg-RX-API-DMAC7.html)
HK (1) HK1041204B (cg-RX-API-DMAC7.html)
HR (2) HRP20010778B1 (cg-RX-API-DMAC7.html)
HU (2) HUP0001632A3 (cg-RX-API-DMAC7.html)
ID (1) ID25704A (cg-RX-API-DMAC7.html)
IE (1) IE20000315A1 (cg-RX-API-DMAC7.html)
IL (3) IL135817A0 (cg-RX-API-DMAC7.html)
IT (1) ITMI20000922A1 (cg-RX-API-DMAC7.html)
LT (1) LT4758B (cg-RX-API-DMAC7.html)
LU (1) LU90569B1 (cg-RX-API-DMAC7.html)
LV (1) LV12560B (cg-RX-API-DMAC7.html)
MX (2) MXPA00003997A (cg-RX-API-DMAC7.html)
NL (1) NL1015027C2 (cg-RX-API-DMAC7.html)
NO (2) NO20002097L (cg-RX-API-DMAC7.html)
NZ (2) NZ504163A (cg-RX-API-DMAC7.html)
PE (1) PE20010071A1 (cg-RX-API-DMAC7.html)
PL (2) PL197813B1 (cg-RX-API-DMAC7.html)
PT (2) PT1173181E (cg-RX-API-DMAC7.html)
SE (1) SE0001518L (cg-RX-API-DMAC7.html)
SG (1) SG98384A1 (cg-RX-API-DMAC7.html)
SI (2) SI1173181T1 (cg-RX-API-DMAC7.html)
SK (1) SK285415B6 (cg-RX-API-DMAC7.html)
SV (1) SV2002000055A (cg-RX-API-DMAC7.html)
TR (1) TR200001132A3 (cg-RX-API-DMAC7.html)
UA (1) UA72248C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000066099A2 (cg-RX-API-DMAC7.html)
ZA (2) ZA200002058B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE399554T1 (de) * 1999-08-03 2008-07-15 Lilly Icos Llc Pharmazeutische zusammensetzung enthaltend tadalafil
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
CA2411010A1 (en) * 2000-06-08 2001-12-13 Lilly Icos Llc Tetracyclic diketopiperazine compounds as pdev inhibitors
EP1305313A1 (en) * 2000-08-02 2003-05-02 Lilly Icos LLC Fused heterocyclic derivatives as phosphodiesterase inhibitors
CA2445620C (en) 2001-06-05 2008-07-08 Lilly Icos Llc Tetracyclic compounds as pde5-inhibitors
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
EP2522343A1 (en) 2006-03-28 2012-11-14 Javelin Pharmaceuticals, Inc. Formulations of Low Dose Diclofenac and Beta-Cyclodextrin
US7495024B2 (en) 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
WO2012107541A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
KR20150056443A (ko) 2013-11-15 2015-05-26 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합제제
JP2019065006A (ja) 2017-09-29 2019-04-25 ハンミ ファーマシューティカルズ カンパニー リミテッド 生産性及び均一性が改善されたタダラフィルを含む固形製剤、及びその製造方法
US20210137919A1 (en) * 2018-02-07 2021-05-13 Smawa Gmbh Pharmaceutical formulations, method for producing a pharmaceutical formulation, and medicament comprising same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
ATE215950T1 (de) 1996-05-10 2002-04-15 Icos Corp Carbolinderivate
CA2288910C (en) * 1997-04-25 2003-06-24 Pfizer Inc. Pyrazolopyrimidinones for sexual dysfunction
WO1999059584A1 (en) * 1998-05-20 1999-11-25 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
WO2000015639A1 (en) 1998-09-16 2000-03-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
CA2346350C (en) * 1998-10-05 2008-01-08 Eisai Co., Ltd. Intraoral quickly disintegrating tablets
AU3724400A (en) * 1999-03-08 2000-09-28 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
EP1173167A4 (en) * 1999-04-30 2004-07-14 Lilly Icos Llc TREATMENT OF FEMALE SEXUAL STIMULATION DISORDERS
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor

Similar Documents

Publication Publication Date Title
BE2014C009I2 (cg-RX-API-DMAC7.html)
BE2012C016I2 (cg-RX-API-DMAC7.html)
BE2011C032I2 (cg-RX-API-DMAC7.html)
BE2010C018I2 (cg-RX-API-DMAC7.html)
BRPI0113085B8 (cg-RX-API-DMAC7.html)
JP2003506639A5 (cg-RX-API-DMAC7.html)
BE2011C041I2 (cg-RX-API-DMAC7.html)
BE2010C040I2 (cg-RX-API-DMAC7.html)
JP2002064579A5 (cg-RX-API-DMAC7.html)
JP2002537099A5 (cg-RX-API-DMAC7.html)
BRPI0113372A8 (cg-RX-API-DMAC7.html)
JP2001212932A5 (cg-RX-API-DMAC7.html)
JP2002025613A5 (cg-RX-API-DMAC7.html)
CN300955183S (zh) 连接件
IN192298B (cg-RX-API-DMAC7.html)
BR122012015772A2 (cg-RX-API-DMAC7.html)
CN3169934S (cg-RX-API-DMAC7.html)
CN3134731S (cg-RX-API-DMAC7.html)
CN3146291S (cg-RX-API-DMAC7.html)
CN3164379S (cg-RX-API-DMAC7.html)
CN3135584S (cg-RX-API-DMAC7.html)
CN3143306S (cg-RX-API-DMAC7.html)
CN3147473S (cg-RX-API-DMAC7.html)
CN3143905S (cg-RX-API-DMAC7.html)
AU2000256911A8 (cg-RX-API-DMAC7.html)